Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02892734
Title Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications

Her2-receptor negative breast cancer

Therapies

Ipilimumab + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.